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A B S T R A C T
Endosomes and lysosomes (endolysosomes) are membrane bounded organelles that play a key role in cell sur-
vival and cell death. These acidic intracellular organelles are the principal sites for intracellular hydrolytic
activity required for the maintenance of cellular homeostasis. Endolysosomes are involved in the degradation of
plasma membrane components, extracellular macromolecules as well as intracellular macromolecules and cel-
lular fragments. Understanding the physiological significance and pathological relevance of endolysosomes is
now complicated by relatively recent findings of physical and functional interactions between endolysosomes
with other intracellular organelles including endoplasmic reticulum, mitochondria, plasma membranes, and
peroxisomes. Indeed, evidence clearly indicates that endolysosome dysfunction and inter-organellar signaling
occurs in different neurodegenerative diseases including Alzheimer’s disease (AD), HIV-1 associated neurocog-
nitive disease (HAND), Parkinson’s disease (PD) as well as various forms of brain cancer such as glioblastoma
multiforme (GBM). These findings open new areas of cell biology research focusing on understanding the
physiological actions and pathophysiological consequences of inter-organellar communication. Here, we will
review findings of others and us that endolysosome de-acidification and dysfunction coupled with impaired
inter-organellar signaling is involved in the pathogenesis of AD, HAND, PD, and GBM. A more comprehensive
appreciation of cell biology and inter-organellar signaling could lead to the development of new drugs to prevent
or cure these diseases.
1. Introduction
Endosomes and lysosomes (hereafter referred to as endolysosomes)
are acidic organelles that degrade plasma membrane components, ex-
tracellular macromolecules, intracellular macromolecules, and cellular
fragments (Orr and Oddo, 2013; Pryor and Luzio, 2009). Endolyso-
somes help to maintain homeostasis of cells through their degradative
roles. These organelles are considered as energy sparing organelles
because they provide amino acids, fatty acids and simple sugars
(Dugail, 2014), and these digestive organelles participate in immune
responses through their proteolytic functions that provide degradation
products presented by major histocompatibility complex (MHC) class II
molecules (Munz, 2012). Beyond their degradative functions, en-
dolysosomes are involved in membrane resealing (Perera and Zoncu,
2016) and apoptosis through mitochondrial destabilization (Repnik and
Turk, 2010). Structural and functional changes to endolysosomes have
been implicated in the pathogenesis of neurodegenerative diseases and
cancer (Colacurcio and Nixon, 2016; Kroemer and Jäättelä, 2005; Olson
and Joyce, 2015). The growing interest in the physical and functional
interactions between organelles has led to increased efforts to
understand better how inter-organellar signaling plays a role in disease
progression especially neurodegenerative diseases and different types
of cancer. Accordingly, we discuss here evidence suggesting that en-
dolysosomes participate in early and upstream pathological signaling
events that are triggered by various disease-relevant insults (Table 1).
2. Endolysosome calcium storage and signaling
Endolysosomes contain many biologically important substances in-
cluding divalent cations. Calcium is known as a universally important
signaling cation that is contained in the lumen of endolysosomes at
concentrations estimated to be about 500 μM; levels approaching those
found in endoplasmic reticulum (ER) (Christensen et al., 2002; Patel
and Cai, 2015). Others and we have shown that endolysosome stores of
calcium are readily releasable (Christensen et al., 2002; Hui et al.,
2015; Shen et al., 2012). The release of endolysosome calcium is
mediated by various transporters including two-pore channels (TPCs)
(Penny et al., 2015). And, calcium released following activation of
TPC2 has been shown to trigger the release of calcium from ER-resident
inositol trisphosphate receptors (IP3Rs) and/or ryanodine receptors
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(RyRs) (Penny et al., 2015) (Fig. 1). Moreover, we have shown that
calcium released from endolysosomes can enhance extracellular cal-
cium influx through N-type calcium channels (NTCCs); a phenomenon
we termed “acidic store-operated calcium entry (aSOCE)” (Hui et al.,
2015) (Fig. 1). Thus, accumulating evidence suggests that endolyso-
some-based events are early and upstream of many downstream sig-
naling pathways in cells and that calcium is involved.
3. Acidic nature of endolysosomes
An important hallmark of endolysosomes is their acidic luminal pH,
which is maintained by different mechanisms such as electrogenic
pumping of protons by vacuolar-ATPase (v-ATPase) in conjunction with
vesicular chloride transporters that effectively shunt membrane po-
tentials to allow a build-up of luminal protons (Ishida et al., 2013). v-
ATPase activity is important not only for the maintenance of the acidic
environment of endolysosomes, but also cytosolic and extracellular pH
(Halcrow et al., 2019). v-ATPases are multi-subunit complexes com-
posed of two major domains; a peripheral V1 domain that contains 8
subunits and hydrolyzes ATP, and an integral membrane V0 domain
that contains 5 subunits and transports H+ (Marshansky et al., 2014;
McGuire et al., 2016). The acidic pH of endolysosomes is critical for the
Table 1
Endolysosomal morpholigical and functional changes and impaired inter-organellar communications in Alzheimer’s disease (AD), HIV associated neurodegenerative
disease (HAND), Parkinson’s disease (PD), and brain cancer. ND: not discussed.







AD + + ND Cataldo et al., 2004; Cataldo et al., 2008; Chen et al., 2010;
Hui et al., 2012a; Kim et al., 2016; Hui et al., 2019a
ND + ND Lee et al., 2010; Avrahami et al., 2013; Wolfe et al., 2013;
Piras et al., 2016
ND ND + Area-Gomez and Schon, 2017
+ ND ND Nakamura et al., 1991; Ii et al., 1993
HAND ND + ND Achim et al., 2009
+ + ND Hui et al., 2012b
+ + ND Chen et al., 2013; El-Hage et al., 2015
ND ND + Huang et al., 2012; Nooka and Ghorpade, 2017
ND + ND Gelman et al., 2005; Soliman et al., 2017
PD ND + ND Cuervo et al., 2004
+ + ND Dehay et al., 2012
+ + ND Bae et al., 2015
ND + ND Rivero-Rios et al., 2019
+ + + Garcia-Sanz et al., 2017
Brain cancer ND + ND Di Cristofori et al., 2015
+ + + Halcrow et al., 2019
Fig. 1. Insult-induced endolysosome deacidification by, for example, HIV-1 Tat and low density lipoprotein (LDL) cholesterol leads to the release of Ca2+ from
endolysosomes. Ca2+ released from endolysosomes can increase influx of calcium from N-type calcium channels (NTCC) channels. Ca2+ overload in cytoplasm can
activate calpains and calcineurin (CaN) enzymes leading to inhibition of long-term potentiation, induction of long-term depression, neuritic atrophy, modification of
neuronal cytoskeleton, and disturbed levels of synaptic plasticity. Cytosolic Ca2+ can trigger Ca2+ release form endoplasmic reticulum (ER) via inositol 1,4,5-
trisphosphate receptors (IP3R), ryanodine receptors (RyR), sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) and presenilin receptors (PSEN). Excessive calcium
taken up by mitochondria through various channels including voltage-dependent anion channels (VDAC) followed by calcium overload can lead to mitochondrial
dysfunction. Ca2+ movement can also occur through mitochondria-associated membrane (MAM) attachments between ER and mitochondria. Therefore, en-
dolysosome de-acidification and dysfunction may be upstream of signaling dysregulation observed in various disease states.
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activity of up to 60 different pH-sensitive hydrolytic enzymes including
proteases, lipases, glycosidases, and nucleases thus enabling the en-
dolysosomes to break down a wide range of endogenous and exogenous
cargo (Xu and Ren, 2015). Endolysosome pH is very tightly controlled
because de-acidification can inhibit the activity of hydrolases that
function optimally at acidic pH and can promote the activity of other
hydrolases that function optimally at pH values closer to neutral
(Colacurcio and Nixon, 2016). Endolysosome de-acidification can in-
crease the generation of undigested substrates, toxic products, and/or
semi-digested intermediates (Colacurcio and Nixon, 2016). De-acid-
ification of endolysosomes can also cause the release of various cations
including calcium from the lumen into the cytoplasm (Penny et al.,
2015). In addition to the critical role in regulating the activity levels of
hydrolytic enzymes, low pH is important for fusion between lysosomes
and autophagosomes to yield autophagolysosomes.
An ever-increasing number of compounds and conditions are now
known to cause endolysosome de-acidification. De-acidification occurs
by basic and weakly-basic drugs, compounds including ammonium
chloride, the anti-malarial drug chloroquine, as well as by the selective
v-ATPase inhibitor, bafilomycin A1; consequences of which include the
release of calcium from endolysosomes (Chen et al., 2018; Hui et al.,
2015; Johannessen et al., 2019) and the suppression of autophagosome-
lysosome fusion (Kawai et al., 2007). Altered endolysosome pH has
been implicated in a growing number of therapeutic drugs’ actions and
human diseases including AD, PD, HAND, and different types of cancers
including GBM (Avrahami et al., 2013; Cai et al., 2012; Chen et al.,
2013; Dehay et al., 2012; Di Cristofori et al., 2015; Feng et al., 2013;
Hui et al., 2012b; Wolfe et al., 2013).
4. Alzheimer’s disease (AD)
AD is the leading cause of dementia worldwide in people older than
65 years of age and currently there are no effective treatments capable
of preventing or reversing the ravages of the disease. AD is character-
ized clinically by progressive memory loss and cognitive impairments.
Pathologically, AD is characterized by the presence of extracellular
senile plaques composed of amyloid β (Aβ) protein, intracellular neu-
rofibrillary tangles composed of hyperphosphorylated tau (P-Tau)
protein, synaptic and neuronal loss, and increased levels of reactive
oxygen species (ROS) (Alzheimer's Association, 2016; De Strooper and
Karran, 2016; Pohanka, 2018; Tarawneh and Holtzman, 2012). At the
subcellular level organelles including endolysosomes, mitochondria,
and ER as well as the process of autophagy appear to play important
roles in AD pathogenesis (Avrahami et al., 2013; Ferreiro et al., 2012).
5. Endolysosomes in AD
Although the pathogenesis of AD remains elusive, growing evidence
has linked endolysosome dysfunction to accelerated amyloidogenesis,
tauopathy, and neurite dystrophy to the development of AD (Nixon,
2017). Amyloid-β precursor protein (AβPP) metabolism is catalyzed by
the amyloidogenic enzymes β- and γ-secretase, and the non-amyloido-
genic enzymes α- and γ-secretase (Zhang et al., 2011). β- and γ-secre-
tases are mainly localized to endolysosomes and endolysosome deaci-
dification increases while endolysosome acidification decreases the
activity of BACE1, the rate limiting enzyme that controls amyloido-
genesis. Endolysosome deacidification with low-density lipoprotein
(LDL) cholesterol enhanced β-secretase activity levels as well as se-
creted and intraneuronal levels of Aβ1-40 and Aβ1-42; effects that were
blocked by mucolipin synthetic agonist MLSA-1 activation of TRPM1
channels and endolysosome acidification (Hui et al., 2012a; Hui et al.,
2019a; Hui et al., 2019b; Khan et al., 2019). It is doubtful that this
effect was unique to LDL cholesterol because, for example, HIV-1 Tat
protein also deacidified endolysosomes, increased the activity of β-se-
cretase, and increased neuronal levels of Aβ (Chen et al., 2013). Indeed,
endolysosome deacidification increases γ-secretase activity and the
production of Aβ1-40 and Aβ1-42 (McLendon et al., 2000). However,
considering that AβPP cleavage occurs mainly on the cell surface
(Parvathy et al., 1999) and not in endolysosomes, pH changes are not
expected to affect non-amyloidogenic metabolism of AβPP.
Because the acidic pH of endolysosomes is critical for the activity of
pH-sensitive β- and γ-secretases and as well as the degradation of Aβ
and aggregated tau, even subtle alkalization (de-acidification) can in-
crease levels of aggregated Aβ and Tau (Aufschnaiter et al., 2017;
Chesser et al., 2013a; Di Domenico et al., 2016; Soliman et al., 2017).
Furthermore, because neurons are extraordinarily polarized cells with
extensive processes that require constant movement of endolysosomes
for membrane trafficking and for the maintenance of synaptic plasticity,
(Nixon, 2017; Nixon and Cataldo, 1995; Nixon and Cataldo, 2006), and
because changes in endolysosome pH have been shown to affect
markedly the movement of endolysosomes in cells, dysregulation of
endolysosome trafficking due to de-acidification could lead to impaired
synaptic integrity (Chen et al., 2013; Eitan et al., 2016; Hui et al.,
2012a; Hui et al., 2012b; Hui et al., 2019a; Jia et al., 2017; Johnson
et al., 2016; Korolchuk et al., 2011; Michael et al., 2018; Shea et al.,
2016).
Associated with AD are findings of endolysosome enlargement, re-
distribution of endolysosomes in neurons, and accumulation of en-
dolysosome substrates in brain (Cataldo et al., 2008; Cataldo et al.,
2004; Chen et al., 2010; Colacurcio et al., 2018; Ii et al., 1993; Kim
et al., 2016; Nakamura et al., 1991; Nixon, 2017; Whyte et al., 2017).
Because neurons are long-lived post-mitotic cells and thus cannot get
rid of waste materials via cell division, endolysosomes are especially
important for the health and demise of neurons (Nixon and Cataldo,
2006). Endolysosome dysfunction also appears to play an early patho-
genic role in AD; endolysosome de-acidification and dysfunction was
found in cultured cell models of AD, brains of AD mouse models, and
fibroblasts from AD patients (Avrahami et al., 2013; Hui et al., 2019a;
McBrayer and Nixon, 2013; Wolfe et al., 2013).
Acidifying endolysosomes by, for example, inhibition of glycogen
synthase kinase 3β (GSK-3β) increased Aβ clearance and improved
behavior in 5xFAD mice (Avrahami et al., 2013). Inhibition of GSK-3β
can restore the activity of the classical autophagy suppressor mamma-
lian target of rapamycin (mTOR) in 5xFAD mouse brain, inhibit au-
tophagy, and acidify endolysosomes (Avrahami et al., 2013). Pre-
senilin1 (PSEN1) is an ER chaperone involved in the maturation and
targeting of the V0a1 subunit of v-ATPase to lysosome membranes. N-
glycosylation of V0a1 is essential for transferring the subunit from the
ER to lysosomes and the subsequent lysosome acidification; this effect is
blocked by PSEN1 ablation and dysfunction (Lee et al., 2010). GSK-3β
inhibition also increased N-glycosylation of V0a1, a modification re-
quired for lysosomal acidification in PSEN1/PSEN2 mutants (Avrahami
et al., 2013). Given that P-Tau tends to aggregate and that aggregated
P-Tau requires lysosome degradation via autophagy (Chesser et al.,
2013b; Guo et al., 2016), endolysosome acidification as a result of GSK-
3β inhibition may also enhance the ability of lysosome to degrade P-
Tau aggregates.
As mentioned, endolysosome pH is maintained mainly through the
activity of v-ATPase. v-ATPase activity is regulated by different me-
chanisms such as reversible assembly of the V1 and V0 domains
(McGuire et al., 2017). In an animal study on the effects of modulating
GSK-3β activity on endolysosome acidity and AD pathology, post
transcriptional modifications of v-ATPase were found to play an im-
portant role in regulating endolysosome pH (Avrahami et al., 2013).
Indeed, in 5xFAD mice N-glycosylation of the V0a1 subunit of v-ATPase
was decreased and endolysosomes were de-acidified. In contrast, en-
dolysosome acidification via inhibition of GSK-3β led to an increase in
Aβ clearance and improvement in 5xFAD mouse behavior (Avrahami
et al., 2013). Furthermore, GSK-3β inhibition decreased Aβ generation
(Cai et al., 2012) and increased levels of cathepsin D (CatD); a pro-
teolytic enzyme that controls Aβ and Tau degradation (Aufschnaiter
et al., 2017; Avrahami et al., 2013; Di Domenico et al., 2016; Soliman
Z. Afghah, et al. Neurobiology of Disease 134 (2020) 104670
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et al., 2017).
Disrupted cholesterol homeostasis and elevated levels of plasma
LDL cholesterol is a robust risk factor for developing AD pathogenesis
(Fiorenza et al., 2013). Considering that the presence of apolipoprotein
E4 (apoE4) allele is the strongest risk factor for developing sporadic AD
and the fact that APOE protein is a major transporter of LDL cholesterol
in brain, the relationship between APOE, LDL cholesterol level, and AD
pathology is receiving fresh attention in AD research (Chen et al., 2014;
Coon et al., 2007; Dhiman et al., 2019; Leduc et al., 2010). Although the
exact mechanism by which APOE4 is involved in AD pathogenesis re-
mains elusive, studies suggest APOE4 is clearly associated with elevated
levels of LDL cholesterol (Cahua-Pablo et al., 2016). Also, elevated le-
vels of LDL cholesterol independent of APOE genotypes are associated
with developing AD pathology such as increased levels of Aβ deposition
in brain and/or tau pathology, and memory impairment in animal
models for AD (Chen et al., 2010; Thirumangalakudi et al., 2008).
Moreover, we have shown that increased levels of circulating choles-
terol which is a risk factor for developing sporadic AD is associated with
endolysosome deacidification (Hui et al., 2012a; Hui et al., 2019a). LDL
cholesterol caused accumulation of β-secretase-1 (BACE-1) in en-
dolysosomes, increased BACE-1 activity levels, and increased amyloi-
dogenesis; these effects were blocked by activating TRPML1 cation
channels and acidifying endolysosomes (Hui et al., 2012a; Hui et al.,
2019a). Therefore, treatments that promote v-ATPase activity and
acidify endolysosomes might have protective effects against develop-
ment of AD pathological hallmarks.
Besides impaired BACE-1 activity, disruption in endolysosome
trafficking of BACE1 can also occur in AD. Under normal conditions
AβPP processing by BACE1 occurs mainly in early endosomes
(Rajendran et al., 2006), but trafficking of AβPP and/or BACE1 can be
impaired because of changes in the levels of cargo receptors and/or
retromer core components. Accordingly, BACE1 and AβPP may reside
longer in early endosomes and the subsequent increase in the β-amy-
loidogenic processing of AβPP could lead to an increase in Aβ (Toh and
Gleeson, 2016).
Changes in endolysosome morphology and impaired endolysosome
function have also been reported in other animal models for AD. In
olfactory bulbs of rabbits fed a cholesterol-enriched diet, a model of
sporadic AD, there were decreases in specific activity levels of acid
phosphatase and CatD as well as decreases in synaptic area. We also
observed increased sizes of endolysosomes, and increased levels of Aβ,
phosphorylated tau, and ApoB-containing cholesterol. Considering the
role of endolysosomes in the degradation of tau protein, tau-pathology
observed in neurons of olfactory bulb indicated impaired endolysosome
function (Chen et al., 2010). We have also found morphological
changes in endolysosomes and endolysosome dysfunction in skeletal
muscles of cholesterol-fed rabbits. Deficits in skeletal muscles are in-
volved in progressive functional problems in AD patients (Chen et al.,
2016) and we observed enlarged endolysosomes containing accumu-
lations of free cholesterol, Aβ, P-Tau and ubiquitin Chen et al., 2019.
Impaired lysosomal protein expression and integrity has also been
shown in post-mortem brain of patients with early-onset familial AD;
there were increased levels of lysosomal-associated membrane protein
1 (LAMP1) and a diffuse spread of CatD (Piras et al., 2016). Dysregu-
lation of the autophagy-lysosomal pathway was also observed; in-
creased accumulations of the autophagic marker microtubule-asso-
ciated protein 1A/1B-light chain 3 (LC3) were observed in LC3-positive
vesicles in frontal cortex localized with P-Tau (Piras et al., 2016).
Nevertheless, relatively little is known about mechanistic links between
endolysosome dysfunction and AD pathogenesis and better under-
standing of such mechanisms may provide new insight into AD patho-
genesis and potentially new therapeutic strategies.
6. Inter-organellar signaling in AD
The mechanisms involved in AD pathogenesis are complex and anti-
amyloidogenic treatments have failed in clinical trials (Cavanaugh
et al., 2014; Selkoe and Hardy, 2016). Of course, there are many pos-
sible reasons for clinical trial failures, but increasingly other morpho-
logical and biochemical changes in AD have been targeted that might
lead to earlier interventions against AD even before the formation of
plaques and neurofibrillary tangles (Area-Gomez and Schon, 2017).
Accordingly, there has been a growing interest in studying other mor-
phological and biochemical changes in AD such as altered phospho-
lipid, calcium, and cholesterol metabolism.
Mitochondrial dysfunction continues to be implicated in the pa-
thogenesis of AD. Changes to mitochondrial function have been re-
ported in sporadic and early onset AD including decreased numbers,
decreased axonal transport of mitochondria, impairments in mi-
tochondrial fusion and fission, and morphological changes such as de-
creased length and increased overall sizes (Albensi, 2019; Lazarov
et al., 2007; Lunnon et al., 2012; Wang et al., 2009; Wang et al., 2008;
Zhu et al., 2013). Dysfunctions in mitochondrial respiratory complexes
I and IV have been reported in AD (Eckert et al., 2011) and such ab-
normal mitochondrial electron activities could lead to disruption in
mitochondrial membrane potentials, decreases in the production of
ATP, and increases in the levels of ROS (Eckert et al., 2011). Opening of
mPTPs has been implicated in AD in part because they are affected by
ROS generation, changes in membrane potential, increases in levels of
intracellular calcium, and the release of pro-apoptotic factors; all of
which can lead to cell death (Albensi, 2019; Du and Yan, 2010). Indeed,
it has been suggested that mPTP inhibitors may serve as potential
therapeutic strategies in AD treatment (Albensi, 2019; Du and Yan,
2010).
Enhanced functions of mitochondria-associated membranes (MAM)
have been observed in cells from AD patients as well as in cellular and
animal models of AD (Area-Gomez and Schon, 2017). MAMs are spe-
cialized lipid raft-like subdomains of ER that physically link mi-
tochondria to ER and increased MAM connections between ER and
mitochondria may be involved in AD pathogenesis (Area-Gomez and
Schon, 2017). Because MAMs are involved in calcium transmission
between ER and mitochondria (Hayashi et al., 2009), up-regulation of
MAM function could lead to calcium dysregulation in AD (Schon and
Area-Gomez, 2013). Endolysosome calcium dysregulation can lead to
altered calcium levels in the cytoplasm, calcium release from ER, cal-
cium influx through cell surface calcium channels, and Ca2+ overload
in mitochondria (Hui et al., 2015; Penny et al., 2015; Supnet and
Bezprozvanny, 2010a).
Intracellular levels of calcium help regulate many different signaling
pathways and is subject to complex spatial and temporal control.
Altered calcium signaling and the involvement of intracellular calcium
stores have long been described for AD pathogenesis (Magi et al., 2016;
Supnet and Bezprozvanny, 2010a). Calcium dysregulation in neuronal
cells and changes in protein levels of proteins involved in Ca2+ sig-
naling have been shown in animal models of familial AD and in brain of
AD patients (Bekris et al., 2010; Bezprozvanny and Mattson, 2008;
Stutzmann et al., 2006; Supnet and Bezprozvanny, 2010b; Veinbergs
et al., 2002). The two major readily releasable stores of intracellular
calcium are ER and endolysosomes; both contain concentrations of
calcium approaching about 500 μM (Christensen et al., 2002; Patel and
Cai, 2015). Impaired calcium homeostasis occurs in aging and even
subtle changes in calcium homeostasis can lead to age-related neuronal
dysfunction (Supnet and Bezprozvanny, 2010b; Toescu and
Verkhratsky, 2007). Endolysosome de-acidification results in the re-
lease of calcium from endolysosomes and the resulting increased levels
of calcium in the cytoplasm can trigger downstream pathways as well as
the release of calcium from ER (Penny et al., 2015). In a study on
calcium signaling in familial AD, enhanced IP3 mediated Ca2+ release
from ER has been reported in skin fibroblasts from AD patients (Ito
et al., 1994). In addition, fibroblasts from asymptomatic patients at risk
for AD showed enhanced release of ER calcium following activation of
IP3 receptors (Etcheberrigaray et al., 1998). Such high levels of
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cytosolic calcium can activate the Ca2+-dependent protein phosphatase
calcineurin (CaN) and such Ca2+-dependent proteases as calpains and
can lead to modification of neuronal cytoskeleton, inhibition of long-
term potentiation, neuritic atrophy, and synaptic loss (Fig. 1). Indeed,
Ca2+ signaling remodeling may be involved in erasing memory by
enhancing the process of long-term depression (Berridge, 2010; Supnet
and Bezprozvanny, 2010a; Trinchese et al., 2008; Vosler et al., 2008).
Mitochondria also are involved in the control of intracellular cal-
cium levels and do so by accumulating Ca2+ from cytoplasm or ER
through the outer mitochondrial membrane (OMM) likely via the vol-
tage-dependent anion channel (VDAC) (Fig. 1). Excessive Ca2+ taken
up by mitochondria (calcium overload) can result in calcium being
released through opening of mitochondrial permeability-transition
pores (MPTP); a process linked to initiation of cell death signaling
cascades (Giacomello et al., 2007; Supnet and Bezprozvanny, 2010a;
Supnet and Bezprozvanny, 2010b). Because disturbances in cytosolic
and mitochondrial calcium can affect multiple calcium signaling path-
ways, mitochondrial pools of calcium have been regarded as good
targets against which therapeutic strategies might be developed for AD
treatment (Supnet and Bezprozvanny, 2010a; Supnet and
Bezprozvanny, 2010b). Dysregulation of neuronal Ca2+ in AD impairs
Ca2+ signaling in mitochondria and leads to mitochondrial dysfunction
and impaired neuronal function (Supnet and Bezprozvanny, 2010b).
Abnormal calcium signaling has also been reported through the binding
of Aβ to AβPP protein. Under normal conditions AβPP protein binds to
G-proteins and stays inactive. However, increased levels of Aβ in AD
brain can induce the release of G protein from AβPP. Activated G-
protein in turn induces calcium dysregulation possibly through reg-
ulating the receptors on ER and plasma membrane leading to influx of
calcium from ER stores or from the extracellular space resulting in cell
death (Shaked et al., 2009). Decreasing calcium uptake by mitochon-
dria using anti-inflammatory drugs (NSAIDs) was suggested to be pro-
tective against AD by inhibiting Ca2+ overload in mitochondria and
subsequent cytochrome c release, and apoptosis and cell death induced
by Aβ (Sanz-Blasco et al., 2008).
Oxidative stress is also involved in AD pathogenesis through al-
tering AβPP processing by increasing the levels of BACE-1 through
activation of c-Jun amino-terminal kinase and p38 mitogen-activated
protein kinase (MAPK) or increasing P-Tau by activation of GSK-3β (Lin
and Beal, 2006; Lovell et al., 2004; Tamagno et al., 2005).
Presenilin mutations can impair intracellular function and com-
munication. Presenilins are transmembrane proteins that play a key
role in regulating ER-calcium dynamics through different mechanisms
including activation of sarco/endoplasmic reticulum Ca2+-ATPase
SERCA pump, and via IP3Rs and RyRs (Corona et al., 2011). Presenilin2
(PSEN2) is involved in transferring calcium between ER and mi-
tochondria, a process that is enhanced in cells expressing PSEN2 mu-
tants (Zampese et al., 2011). Brains of zebrafish harboring a single early
onset AD (EOAD)-like mutation in their PSEN1-orthologous gene dis-
played profound effects on cellular components including plasma
membranes, mitochondria, and membrane transporter activity parti-
cularly v-ATPases (Newman et al., 2019).
PSEN2 plays a critical role in modulating intracellular Ca 2+
homeostasis independently of its γ-secretase activity. PSEN2 mutants
show disruptions in autophagy resulting from a reduction in recruit-
ment of the GTPase Rab7 to autophagosomes and impairment of au-
tophagosome-lysosome fusion. Moreover, the effect of FAD-PSEN2
mutants on autophagy is related to its ability to partially deplete ER
Ca2+ and decrease levels of cytosolic Ca2+ following IP3-linked cell
stimulations (Fedeli et al., 2019; Zatti et al., 2004). It has been sug-
gested that PSEN mutations might enhance IP3R- and RyR-mediated
Ca2+ efflux as a compensatory response for increased levels of ER Ca2+
(Wang and Zheng, 2019). Ca 2+ channels on plasma membranes also
could be affected by PSEN mutations; PSEN 1 mutants cleave stromal
interaction molecule 1 (STIM1) and cause dysfunctions in store-oper-
ated calcium entry (SOCE) (Tong et al., 2016). Mutations in PSEN can
also impair mitochondrial/ER interactions by targeting MAMs and in-
ducing the transfer of Ca2+ between ER and mitochondria (Wang and
Zheng, 2019).
Based on the findings of us and others, endolysosome dysfunction
and altered inter-organellar signaling might be considered to be early
and upstream trigger in the development of pathological changes as-
sociated with AD.
7. HIV-1 associated neurocognitive disorder (HAND)
Nearly 40 million people were living worldwide with HIV-1 (human
immunodeficiency virus) in 2017 (Global HIV and AIDS statistics,
2018). People living with HIV-1 (PLWH) who have been taking anti-
retroviral therapeutic (ART) drugs are now living almost full life-spans
and fewer PLWH are dying from acquired immunodeficiency disease
(AIDS) (Saylor et al., 2016). However, 40–50% of PLWH suffer from
HIV-associated neurocognitive disorders (HAND) that varies in in-
tensity from so-called asymptomatic HAND to HIV-1 associated de-
mentia (Ghosh et al., 2017). Although the pathogenesis of HAND is not
entirely clear, others and we have demonstrated the involvement of
such virotoxins as HIV-1 transactivator of transcription protein (Tat),
envelope glycoprotein gp120, negative factor (Nef), and viral protein r
(Vpr) (Buscemi et al., 2007; Chen et al., 2013; Datta et al., 2019;
Haughey and Mattson, 2002; Hui et al., 2012b; King et al., 2006;
Kovalevich and Langford, 2012). Tat is a well-studied HIV-1 viral
protein that has been found to be present in the CSF of even virally-
suppressed patients and that induces neuronal excitation and calcium
release from intracellular stores leading to disruption of calcium
homeostasis in neuronal cells and neurotoxicity (Haughey et al., 1999;
Haughey and Mattson, 2002; Hui et al., 2012b; Johnson et al., 2013).
8. Endolysosomes in HAND
Changes in pH, membrane integrity, and morphology of endolyso-
somes have been considered by others and us as pathological features in
HAND (Achim et al., 2009; Hui et al., 2012b). As is typical of agents
that de-acidify endolysosomes, treatment of primary rat hippocampal
neurons with HIV-1 Tat resulted in endolysosomes being larger and
prone to increased clumping (Chen et al., 2013; Hui et al., 2012b).
Distribution of endolysosomes within cells is affected by HIV-1 Tat.
While control cells displayed a perinuclear and evenly distributed
puncta pattern for endolysosomes, cells treated with HIV-1 Tat showed
a diffuse pattern in the cytoplasm (Hui et al., 2012b). Moreover, HIV-1
Tat-induced impairment of endolysosome membrane integrity and en-
dolysosome de-acidification was also reported by others and us (Chen
et al., 2013; El-Hage et al., 2015; Hui et al., 2012b).
The underlying mechanisms involved in endolysosome de-acid-
ification by HIV-1 Tat are not well understood, but may include the
arginine-rich sequence of HIV-1 Tat protein and the effects of Tat on
endolysosome membrane integrity. HIV-1 Tat has an arginine-rich do-
main between amino acid residues 49 and 57, and other arginine-rich
peptides such as penetratin, Antennapedia protein, and oligoarginines
have all been found to deacidify endolysosomes (L. Hui, X. Chen and J.
D. Geiger, unpublished data). Disrupting the membrane integrity of
endolysosomes is another mechanism whereby HIV-1 Tat could induce
endolysosome deacidification (Hui et al., 2012b). Moreover, enlarged
and clustered lysosomes and autophagosomes have been observed in
brain of HIV-infected patients who were taking ART (Achim et al.,
2009). Interestingly, these lysosomal-autophagic structures exhibited a
significant accumulation of Aβ in neurons from the frontal cortex sug-
gesting disturbed Aβ clearance in these cells which might result in
cognitive impairment in older PLWH (Achim et al., 2009). Prolonged
ART may contribute to elevated levels of Aβ deposition; implicated
mechanisms include disrupted axonal transport of AβPP, inhibition of
insulin degradation enzyme (IDE), or suppression of the major Aβ de-
grading enzyme neprilysin (Daily et al., 2006; Green et al., 2005). In
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brain of HIV-1 infected patients there was an accumulation of lyso-
somes in macrophages, astrocytes, microglial and glial cells (Gelman
et al., 2005; Gelman et al., 1997). In patients with HIV-1 associated
dementia, lysosome expansion was noted in subcortical white matter
(Gelman et al., 2005; Gelman et al., 1997). Thus, endolysosomes are
impaired in HAND and more studies are needed to clarify the me-
chanisms involved in endolysosome dysfunction in the pathogenesis of
HAND.
9. Inter-organellar signaling in HAND
A limited number of studies have been published regarding the role
of inter-organellar signaling in HAND. The HIV protein Vpr is trans-
ported from ER to mitochondria via MAMs where it leads to an increase
in the permeability of mitochondrial outer membranes, mitochondrial
deformation, increase in bulging in MAMs, and a loss in mitochondrial
membrane potential (Huang et al., 2012). The possible role of ER stress
and mitochondrial dysfunction has been also studied in primary human
astrocytes exposed to HAND-relevant stimuli (HIV-1 virions, in-
flammatory stimuli, and ARTs); the observed increases in intracellular
calcium signaling in cells treated with IL-1β and the nucleoside reverse
transcriptase inhibitor abacavir involved calcium release from ER. The
subsequent mitochondrial permeability transition pore (mPTP) opening
observed in these cells demonstrated that ER stress was upstream of
mitochondrial depolarization which could lead to apoptosis (Nooka and
Ghorpade, 2017). Calcium regulation in HAND (Haughey and Mattson,
2002) might now be reevaluated from the context of inter-organellar
signaling especially because of findings that significant reductions in
lysosomal calcium stores as a result of accumulation of sphingosine
leads to impaired endocytic fusion and trafficking (Lloyd-Evans et al.,
2008) and can lead to dysregulation of calcium homeostasis in ER by
affecting the function of calcium channels (Platt et al., 2012).
10. Endolysosomes in Parkinson’s disease (PD)
Parkinson’s disease is the second-most common neurodegenerative
disorder pathologically characterized by death of dopaminergic neu-
rons in the substantia nigra pars compacta and the presence of Lewy
bodies (Dehay et al., 2012; Poewe et al., 2017). Impaired lysosomal
acidification and function including decreased degradation of lyso-
somal substrates and reductions in proteolytic enzyme activity of CatD
has been shown in fibroblasts derived from patients with PD harboring
ATP13A2 mutations and in stable ATP13A2-knockdown dopaminergic
cell lines. ATP13A2 is a lysosomal type 5 P-type ATPase linked to au-
tosomal recessive familial parkinsonism; there are reduced levels in
dopaminergic nigral neurons derived from PD patients with a high-level
of accumulation in Lewy bodies. Restoring the protein level of
ATP13A2 in ATP13A2-mutant/depleted cells rescued lysosomal func-
tion and resulted in decreased cell death (Dehay et al., 2012). En-
dolysosome dysfunction in PD has also been linked to the gene en-
coding leucine-rich repeat kinase 2 (LRRK2) (Vidyadhara et al., 2019).
LRRK2 is involved in different intracellular vesicular trafficking path-
ways such as endolysosomal degradative pathways (Gomez-Suaga
et al., 2014). For example, degradation of epidermal growth factor re-
ceptor (EGFR) is regulated by LRRK2 and is impaired in cells expressing
LRRK2 pathogenic variants. LRRK2-mediated deficit in EGF degrada-
tion and endolysosomal membrane trafficking were rescued through
expression of active Rab8A membrane protein, a substrate for LRRK2
(Rivero-Rios et al., 2019). Lysosome dysfunction in PD has also been
linked to mutations in GBA1 gene (Bae et al., 2015); GBA1 encodes β-
glucocerebrosidase 1 (GCase 1) and is a significant genetic risk factor
for PD (O'Regan et al., 2017). Indeed deficiency of GCase 1, a lysosomal
hydrolase, is sufficient to cause accumulation of α-synuclein aggregates
and lysosomal dysfunction including accumulation of lysosomal sub-
strates and accumulation of enlarged vacuolar structures in human
neuroblastoma cell lines (Bae et al., 2015). Moreover, lysosomal
accumulation of cholesterol has been reported in fibroblasts from PD
patients harboring N370S-GBA1 mutation (Garcia-Sanz et al., 2017).
11. Inter-organellar signaling in PD
Mutations in PTEN-induced putative kinase (PINK)1, Parkin and DJ-
1 are associated with PD pathogenesis (Bonifati et al., 2004; Cookson
et al., 2008; Pilsl and Winklhofer, 2012; Scarffe et al., 2014). DJ-1 is a
multifunctional protein that plays a key role in protecting cells against
oxidative stress (van der Merwe et al., 2015) and inhibiting the for-
mation of α-synuclein aggregates; mutant forms of DJ-1 have been
linked to autosomal recessive early onset PD (Bonifati et al., 2003a;
Bonifati et al., 2003b; Shendelman et al., 2004). Mitochondrial kinase
PINK1 is involved in recruiting Parkin from cytosol to mitochondria,
inducing Parkin-mediated mitophagy and increasing the ubiquitination
activity of Parkin (Lazarou et al., 2013). When mitochondria become
depolarized, PINK1 accumulates at the OMM where it causes the ubi-
quitination of mitochondrial substrates and subsequent mitophagy in-
itiation (Liu et al., 2019; van der Merwe et al., 2015). The interactions
of Parkin with DJ-1 at the OMM helps control oxidative stress (van der
Merwe et al., 2015).
ER–mitochondria associations are altered in PD. Further, PD-related
mutations in genes encoding proteins localized in mitochondria and
MAMs may be involved in dysregulation of ER-mitochondria signaling
(Gómez-Suaga et al., 2018). PINK1 and Parkin both localize to MAMs
upon mitochondrial depolarization (Gelmetti et al., 2017). Location of
PINK1 to MAMs may be important for recruitment of autophagy ma-
chinery, while excitotoxicity in neurons triggers the translocation of
Parkin into mitochondrial/ER junctions (Gómez-Suaga et al., 2018; Van
Laar et al., 2015). Moreover, mutations in DJ-1 gene have been linked
to autosomal recessive early-onset parkinsonism (Klein and
Westenberger, 2012). DJ-1 protein is localized to MAMs and DJ-1
overexpression increases mitochondrial Ca2+ uptake and ER–mi-
tochondria associations (Ottolini et al., 2013). On the other hand, de-
creased DJ-1 levels reduces mitochondrial Ca2+ uptake and induces
mitochondria fragmentation (Ottolini et al., 2013).
Mutations in the gene encoding Parkin protein are involved in the
pathogenesis of autosomal recessive early-onset PD (Hunn et al., 2015).
Parkin, an E3 ubiquitin ligase, regulates endolysosomes by modulating
tubular and multivesicular regions as well as exosome secretion (Song
et al., 2016). Parkin also stabilizes and activates Rab7 thus suggesting
that Rab7 deregulation may be involved in the increased exosome se-
cretion observed in Parkin-deficient cells (Song et al., 2016).
Synucleinopathy is caused by abnormal accumulations of ag-
gregated alpha-synuclein protein (McCann et al., 2014). Synucleino-
pathy can result from synuclein alpha (SNCA) gene triplication
(Singleton et al., 2003) as well as from lysosome dysfunction as ob-
served in the lysosomal storage disease known as Gaucher disease.
Thus, similar mechanisms might be involved in PD pathogenesis
(Mazzulli et al., 2016; Nixon, 2013; Wong et al., 2004). Indeed, α-sy-
nuclein accumulation has been shown to affect lysosome hydrolase
trafficking leading to endolysosome dysfunction and impair the locali-
zation of the small GTPase Rab1a, a key regulator of vesicular protein
transport from ER to Golgi compartments (Mazzulli et al., 2016).
Impaired endolysosome function by α-synuclein has been im-
plicated in the pathogenesis of PD. Although wild-type α-synuclein can
be degraded efficiently once transferred to endolysosomes through
chaperone-mediated autophagy (CMA), mutant forms of α-synuclein
block lysosomal uptake and impair protein degradation by CMA
(Cuervo et al., 2004). Further, variants of lysosomal genes observed in
PD may increase the generation of oligomeric and fibrillar forms of α-
synuclein (Klein and Mazzulli, 2018). Gene mutations involved in PD
have been implicated in mitochondrial dysfunction and ROS production
observed in PD which could further lead to lysosomal dysfunction and
the formation of α-synuclein aggregates (Klein and Mazzulli, 2018).
α-Synuclein aggregates can also block the trafficking of
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glucosylceramidase (GlcCerase), a lysosomal enzyme that hydrolyzes
glucosylceramide into free ceramide and glucose (Mazzulli et al., 2011;
Mazzulli et al., 2016). Moreover, in brain of PD patients a deficiency of
GlcCerase has been reported (Murphy et al., 2014). Therefore, accu-
mulation of α-synuclein and the subsequent impaired in lysosomal
trafficking could play a role in PD pathogenesis (Klein and Mazzulli,
2018).
Leucine rich-repeat kinase 2 (LRRK2) is a kinase involved in cellular
processes such as vesicular trafficking, mitochondrial dynamics, au-
tophagy, oxidative stress, and neuronal toxicity (Gomez-Suaga et al.,
2012a; Heo et al., 2010; Ho et al., 2018; Nguyen et al., 2011; Shin et al.,
2008; Wang et al., 2012). LRRK2 has also been linked to mitochondrial
dysfunction in PD; decreases in mitochondrial membrane potential and
ATP levels were observed in skin biopsies from PD patients possessing
LRRK2 G2019S mutations (Liu et al., 2008; Mortiboys et al., 2010).
LRRK2 G2019S mutations cause mitochondrial elongation and increased
fusion between mitochondria (Mortiboys et al., 2010). Further evidence
of the deleterious effects of mutant LRRK2 comes from findings that
LRRK2 G2019S-induced mtDNA damage is LRRK2 kinase activity de-
pendent, that mtDNA damage was blocked with a LRRK2 kinase in-
hibitor, and that this mtDNA damage was not observed in neurons
expressing LRRK2 wild type or LRRK2 D1994A mutant (kinase dead).
Interestingly, patient-derived lymphoblastoid cell lines harboring the
G2019S mutation showed increased mtDNA damage that was blocked
by a LRRK2 kinase inhibitor (Howlett et al., 2017).
Similar evidence comes from in vivo studies. Significant mi-
tochondrial abnormalities consistent with mitochondrial fission arrest
were found in the striatum of knock-in mice harboring the G2019S
LRRK2 mutation (Yue et al., 2015). Further, interactions between mu-
tant LRRK2 G2019S and fission dynamin-related protein 1 (Drp1) protein
promoted mitochondrial fragmentation while inhibiting Drp1 or ex-
pressing the mutant form of Drp1, corrected excessive autophagy, and
reduced mitochondrial fragmentation, lysosomal hyperactivity and
neurite shortening (Su and Qi, 2013; Wang et al., 2012). Underlying
mechanisms by which mutant LRRK2 are involved include calcium
dysregulation, increased formation of autophagosomes through the
activation of the calcium-dependent protein kinase kinase-b (CaMKK-
b)/adenosine monophosphate-activated protein kinase (AMPK), as well
as decreased numbers of acidic lysosomes and activation of nicotinic
acid adenine dinucleotide phosphate (NAADP)-sensitive two-pore
channels (TPCs) located on acidic stores (Gomez-Suaga et al., 2012b).
Although the mechanisms involved in impaired inter-organellar
crosstalk observed in PD are not clear, evidence suggests that damaged
ER–mitochondria signaling may represent a new insight into PD pa-
thogenesis and new drugs may target these pathways to prevent or cure
PD.
12. Endolysosomes in cancer
Metastatic cancer cells show higher expression levels of lysosomal
proteins (Saitoh et al., 1992), which could suggest a higher level of
lysosomal activity. Glioblastoma multiforme (GBM) is the most
common, life-threatening malignant brain tumor in adults; 16% of all
primary brain tumors (Michael et al., 2018; Shea et al., 2016). GBM is
typically characterized by high tumor heterogenicity, rapid develop-
ment of primary tumors, high levels of angiogenesis, presence of hy-
perplastic blood vessels, and areas of necrotic tissue (Halcrow et al.,
2019; Irtenkauf et al., 2017; Lee et al., 2018; Veeravagu et al., 2008).
Acidic extracellular pH near GBM tumors is involved in tumorigenesis
through increases in apoptosis resistance, autophagy and angiogenesis,
and promotion of tumor invasion (Halcrow et al., 2019). v-ATPase
upregulation has been identified to be involved in the pathogenesis of
GBM while v-ATPase inhibition was protective against the disease. In
GBM there is a significant upregulation of the ATP6V1G1 subunit of v-
ATPase and knockdown of ATP6V1G1 subunits as well as v-ATPase
inhibition with bafilomycin A1 resulted in increased levels of tumor cell
death. Bafilomycin A1 reversed lysosome acidification in cancer stem
cells enriched in neurospheres isolated from GBM patients (Di Cristofori
et al., 2015). Thus, lysosome de-acidification and the use of v-ATPase
inhibitors might help halt GBM progression. Considering that lysosomal
acidification is observed in cancer and that lysosomal de-acidification
causes apoptosis (Di Cristofori et al., 2015; Nilsson et al., 2004), lyso-
somal de-acidification could be a potential therapeutic strategy against
cancer.
13. Inter-organellar signaling in cancer
Dysregulation of inter-organellar signaling may be a potential factor
involved in the pathogenesis of GBM (Halcrow et al., 2019). Moreover,
it has been reported that inducing apoptosis using sphingosine leads to
the release of lysosomal proteolytic enzymes in cytosol and activation
of apoptotic cascades suggesting proteases such as CatD act upstream of
changes in mitochondrial membrane potential and the caspase cascade
(Kågedal et al., 2001). Therefore, proteolytic enzymes could be in-
volved in apoptosis either directly through the activation of pro-cas-
pases or indirectly by the effect of proteases on mitochondrial mem-
branes and release of pro-apoptotic factors such as cytochrome c
(Guicciardi et al., 2000; Ishisaka et al., 1999; Kågedal et al., 2001;
Roberg et al., 1999). More studies are required to clarify how impaired
inter-organellar cross talk could be involved in the pathogenesis of
cancer and such findings could lead to the development of new drugs
against cancer.
14. Drug development involving endolysosomes
Drug delivery approaches now take advantage of the process of
endocytosis and the targeting of receptors and ligands. Indeed, na-
noscale drug carriers targeting endolysosomes show promising poten-
tial for the treatment of cancer, Alzheimer's disease, Parkinson’s dis-
ease, and lysosomal storage diseases (Bareford and Swaan, 2007;
Kilpatrick et al., 2015; Rappaport et al., 2016). Because of the upre-
gulation of cell-surface receptors in some diseases, there is greater
specificity of action to endolysosomes (Bareford and Swaan, 2007). For
example, pharmacological activation of transcription factor EB (TFEB),
a master regulator of the autophagy lysosomal pathway, using the en-
docytosed drug 2-hydroxypropyl-β-cyclodextrin (HPβCD), promoted
autophagic clearance of α-synuclein (Kilpatrick et al., 2015). However,
the use of at least some nanoparticles may be problematic because some
have been found to cause endolysosome deacidification and increased
amyloidogenesis (Ye et al., 2019).
15. Future perspective
Extracellular vesicles (EVs) are cell-derived membrane-bound ve-
sicles released from cells into extracellular spaces (Shi et al., 2019).
These vesicles, comprising exosomes originating from the endosomal
system, and microvesicles formed by budding from plasma membranes,
contain nucleic acid and proteins (Shi et al., 2019; van Niel et al.,
2018). It has been suggested recently that EVs are capable of transiting
from the CNS to the peripheral circulation (Shi et al., 2019). Although
more studies are required to clarify the exact mechanisms, EVs origi-
nating from multivesicular bodies can cross the blood-brain barrier and
enter other cells by endocytosis (Matsumoto et al., 2017; Record et al.,
2011; Shi et al., 2014; Shi et al., 2019). Therefore, EVs may afford di-
agnostic opportunities because they carry accessible biomarkers and
endolysosome signaling pathways regulate EVs secretion. Of relevance,
neurally-derived blood exosomes can predict the development of AD up
to 10 years before the onset of clinical signs; the levels of P-S396-tau, P-
T181-tau and Aβ1-42 were higher in AD patients compared to people at
preclinical stages (Fiandaca et al., 2015).
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16. Summary
Endolysosome dysfunction continues to be observed in AD, HAND,
PD, cancer, and lysosome storage diseases. This dysfunction appears to
be upstream of mechanistic events including impaired calcium home-
ostasis in other organelles. Considering the massive health care cost for
neurodegenerative diseases and cancer, studies focusing on mechan-
isms involved in the pathogenesis of these diseases could have a sub-
stantial impact economically, socially, and clinically. While a complete
understanding of the pathogenesis of AD, HAND, PD and different
forms of cancer such as GBM remains elusive, current studies provide
strong evidence supporting the role of endolysosomes dysfunction and
impaired inter-organellar signaling in the development of these dis-
easess. Future studies in these areas may lead to the development of
new therapeutic strategies targeting endolysosomes.
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